Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Study uncovers translation control mechanisms driving tumor growth and therapy resistance (opens in a new tab)

news-medical.net · 2026-11-03

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of eight claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 4 supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    published today in Nature Cell Biology

  • Cited as backgroundpresented as earlier work

    a study the St. Jude team published in Nature in 2023

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredThe results were published today in Nature Cell Biology.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not include publication venue or publication date information, so the statement that the results were published today in Nature Cell Biology cannot be verified from the provided profile.

Claim 2 of 8Not coveredThe METTL13 enzyme modifies eEF1A at lysine 55, and this modification was previously known to increase protein synthesis and promote tumor growth, but how it affects translation elongation and tumor growth was unknown.View evidenceHide evidence

Why this verdict

The profile supports that METTL13 catalyses eEF1A K55 dimethylation and that the study investigates its effect on decoding/pro-oncogenic protein synthesis. However, the claim’s historical framing—what was previously known about increased protein synthesis/tumor growth and what was unknown before this paper—is not established in the abstract-level profile.

1

Study evidence

eEF1A dimethylation at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner.

“Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing.”
Claim 3 of 8Not coveredIn healthy pre-clinical models, knocking out METTL13 did not cause toxic effects.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile does not report healthy preclinical toxicity experiments or lack of toxic effects after METTL13 knockout. This may require full-text evidence, but it is not verifiable from the provided abstract-depth profile.

Claim 4 of 8Not coveredHigher METTL13 activity correlated with poor prognosis in patients with lung adenocarcinoma and pancreatic ductal adenocarcinoma, and the authors suggested it may be useful as a prognostic tool.View evidenceHide evidence

Why this verdict

The profile supports a related but different human association: among patients receiving a KRASG12C inhibitor, computationally inferred METTL13 activity was associated with inferior clinical response. The supplied abstract-level profile does not verify the broader claim about poor prognosis in lung adenocarcinoma and pancreatic ductal adenocarcinoma, lower survival, or use as a general prognostic tool.

1

Study evidence

Among patients receiving a KRASG12C inhibitor, inferred METTL13 activity was associated with inferior clinical response.

“Among patients receiving a KRASG12C inhibitor, inferred METTL13 activity was associated with inferior clinical response.”
Claim 5 of 8SupportedScientists at St. Jude Children's Research Hospital identified how one factor involved in mRNA decoding can be altered, identifying potential cancer origins and new targets for KRAS-related treatment resistance.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core lead framing: METTL13-mediated eEF1A K55 methylation affects codon-selective mRNA decoding and pro-oncogenic protein synthesis, including KRAS-related translation, and METTL13 ablation/targeting is presented as relevant to KRASG12C-inhibitor resistance in preclinical models. The wording is broad, but the claim is framed around potential origins/targets rather than established clinical use.

1

Study evidence

eEF1A dimethylation at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner.

“Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing.”
2

Study evidence

METTL13 knockdown in cancer cells reduced translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, explicitly including KRAS.

“In cancer cells, METTL13 knockdown reduced translation of oncogenic mRNA enriched in eEF1AK55me2-dependent codons, including KRAS”
Claim 6 of 8SupportedUsing cell lines lacking METTL13 and single-molecule imaging, the team demonstrated that eEF1AK55me2 affects mRNA decoding in kinetic and structural terms.View evidenceHide evidence

Why this verdict

The profile states that proteomic profiling and single-molecule imaging showed eEF1AK55me2 increases decoding efficiency, and that METTL13 perturbation in cancer cells reduced translation of codon-enriched oncogenic mRNAs. The abstract-level profile supports the core claim that the team used these approaches to demonstrate effects on mRNA decoding, though it does not provide detailed imaging parameters or all structural specifics.

1

Study evidence

eEF1A dimethylation at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner.

“Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing.”
2

Study evidence

METTL13 knockdown in cancer cells reduced translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, explicitly including KRAS.

“In cancer cells, METTL13 knockdown reduced translation of oncogenic mRNA enriched in eEF1AK55me2-dependent codons, including KRAS”
Claim 7 of 8SupportedThe axis promotes efficient translation of a subset of codons that are enriched in oncogenes, such as KRAS.View evidenceHide evidence

Why this verdict

The profile supports that eEF1AK55me2 selectively enhances decoding of particular codons and preferentially increases synthesis of pro-oncogenic proteins. It also states that METTL13 knockdown reduced translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, explicitly including KRAS.

1

Study evidence

eEF1A dimethylation at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner.

“Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing.”
2

Study evidence

METTL13 knockdown in cancer cells reduced translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, explicitly including KRAS.

“In cancer cells, METTL13 knockdown reduced translation of oncogenic mRNA enriched in eEF1AK55me2-dependent codons, including KRAS”
Claim 8 of 8SupportedThe team observed stymied growth of KRAS-inhibitor–resistant tumors in animal models when METTL13 disruption was examined as a way to overcome KRAS-related treatment resistance.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a causal preclinical intervention claim in animal models: METTL13 loss inhibited growth of sotorasib-resistant KRASG12C lung adenocarcinoma syngeneic tumors and patient-derived xenografts, and METTL13 ablation mitigated sotorasib resistance and extended survival in an autochthonous relapsed KRASG12C-driven lung adenocarcinoma model.

1

Study evidence

METTL13 loss inhibited growth of sotorasib-resistant KRASG12C lung adenocarcinoma syngeneic tumours.

“METTL13 loss inhibited the growth of KRASG12C inhibitor (sotorasib)-resistant lung adenocarcinoma syngeneic tumours”
2

Study evidence

METTL13 loss inhibited growth of sotorasib-resistant KRASG12C lung adenocarcinoma patient-derived xenografts.

“METTL13 loss inhibited the growth of KRASG12C inhibitor (sotorasib)-resistant lung adenocarcinoma ... patient-derived xenografts.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Synonymous codon recoding can bypass the METTL13/eEF1AK55me2 dependency and reverse the translation defect, supporting codon-sequence specificity.

    This is a material causal-rescue experiment in the profile, but the story presentation does not mention synonymous recoding or the rescue logic.

    From synonymous recoding rescue experiments

  • The human clinical association in the profile is specifically that inferred METTL13 activity was associated with inferior clinical response among patients receiving KRASG12C inhibitors.

    The story instead frames the patient finding as poor prognosis in lung adenocarcinoma and pancreatic ductal adenocarcinoma and possible prognostic use. That does not accurately reflect the specific abstract-level clinical element: inferred METTL13 activity associated with inferior response to KRASG12C-inhibitor treatment.

    From observational clinical cohort analysis

  • The patient association is observational and based on computationally inferred METTL13 activity rather than direct measurement; the abstract provides no cohort size, response definition, covariate adjustment, effect size, confidence interval, or p-value.

    The story mentions that patient-prognosis findings are suggestive rather than established clinical practice, but it does not convey the more specific interpretation-changing limitations around inferred biomarker activity, observational design, and missing quantitative/statistical details.

    From observational clinical cohort analysis

4 things the story did carry across
  • METTL13-catalysed eEF1A K55 dimethylation selectively enhances decoding efficiency for specific codons, especially under-represented codons with weak wobble pairing, reshaping translation toward pro-oncogenic proteins.
  • In cancer cells, METTL13 loss reduces translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, including KRAS.
  • METTL13 loss or ablation mitigates KRASG12C-inhibitor resistance and improves tumor control/survival across multiple in vivo cancer models, including syngeneic tumors, PDX models, and an autochthonous relapsed KRASG12C-driven lung adenocarcinoma model.
  • The in vivo resistance findings are preclinical and do not establish an approved therapy or clinical efficacy of METTL13 targeting in patients.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroMETTL13-catalysed eEF1A K55 dimethylation (eEF1AK55me2) selectively enhances decoding efficiency for specific codons (notably under-represented codons with weak wobble pairing), thereby reshaping the translated proteome toward pro-oncogenic proteins.Expand

In plain English

The study reports that METTL13-catalysed dimethylation of eEF1A at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner—particularly enhancing decoding of under-represented codons with weak wobble-position base pairing—leading to increased synthesis of pro-oncogenic proteins. This conclusion is supported by quantitative proteomic profiling and single-molecule imaging measurements of decoding/translation dynamics, and is further linked to reduced translation of affected oncogenic mRNAs (including KRAS) after METTL13 knockdown and reversal by synonymous recoding.

Key findings

  • eEF1A dimethylation at K55 (eEF1AK55me2) increases translation decoding efficiency in a codon-selective manner.
  • The decoding enhancement is preferential for under-represented codons with weak wobble-position base pairing.
“Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroIn cancer cells, METTL13 loss reduces translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons (including KRAS), and synonymous codon recoding can bypass this dependency and reverse the translation defect.genetic perturbation + translation readouts (codon-stratified)Expand

In plain English

In cancer cell models, knockdown or loss of METTL13 reduces translation of oncogenic mRNAs that are enriched for eEF1AK55me2-dependent codons (explicitly including KRAS). Synonymous recoding of KRAS to use eEF1AK55me2-independent codons reverses the translation defect, indicating the dependency is codon-sequence specific.

Key findings

  • METTL13 knockdown in cancer cells reduced translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons, explicitly including KRAS.
  • Synonymous recoding of KRAS to use eEF1AK55me2-independent codons reversed the translation defect caused by METTL13 loss, indicating the dependency is determined by codon usage.
“In cancer cells, METTL13 knockdown reduced translation of oncogenic mRNA enriched in eEF1AK55me2-dependent codons, including KRAS”
What this piece can’t prove

2 further details could not be confirmed from the summary.

3in vitroIn cancer cells, METTL13 loss reduces translation of oncogenic mRNAs enriched for eEF1AK55me2-dependent codons (including KRAS), and synonymous codon recoding can bypass this dependency and reverse the translation defect.synonymous recoding rescue experimentsExpand

In plain English

Synonymous codon recoding of oncogenic transcripts (including KRAS) from eEF1AK55me2-dependent to eEF1AK55me2-independent codons restored their translation in cancer cells following METTL13 loss, providing a causal test that codon identity underlies the METTL13/eEF1AK55me2-dependent translation defect.

Key findings

  • Synonymous recoding of oncogenic mRNAs (including KRAS) to eEF1AK55me2-independent codons reversed the reduction in translation caused by METTL13 loss in cancer cells.
“synonymous recoding with eEF1AK55me2-independent codons reversed this effect.”
What this piece can’t prove
  • Details of construct design, the full set of recoded genes, exact assays used for translation quantification, and statistical analysis are not available in the provided text.
  • Reported findings are described for cancer cells; the abstract does not define the range of cell types or in vivo validation for the recoding rescue specifically.

1 further detail could not be confirmed from the summary.

4in vivo animalTargeting/ablating METTL13 mitigates resistance to KRASG12C inhibitors (e.g., sotorasib) and improves tumour control and survival in multiple in vivo cancer models (syngeneic tumours, PDX, and autochthonous relapsed KRASG12C-driven lung adenocarcinoma).syngeneic tumour modelExpand

In plain English

In an immunocompetent syngeneic lung adenocarcinoma model bearing sotorasib-resistant KRASG12C tumours, loss of METTL13 inhibited tumour growth.

Key findings

  • METTL13 loss inhibited growth of sotorasib-resistant KRASG12C lung adenocarcinoma syngeneic tumours.
“METTL13 loss inhibited the growth of KRASG12C inhibitor (sotorasib)-resistant lung adenocarcinoma syngeneic tumours”
What this piece can’t prove
  • Unclear whether METTL13 targeting was tumour-cell-specific versus systemic, and whether immune effects contributed in the immunocompetent syngeneic context.

3 further details could not be confirmed from the summary.

5in vivo animalTargeting/ablating METTL13 mitigates resistance to KRASG12C inhibitors (e.g., sotorasib) and improves tumour control and survival in multiple in vivo cancer models (syngeneic tumours, PDX, and autochthonous relapsed KRASG12C-driven lung adenocarcinoma).patient-derived xenograft (PDX) experimentExpand

In plain English

In patient-derived xenograft (PDX) models of sotorasib-resistant KRASG12C lung adenocarcinoma, loss of METTL13 inhibited tumour growth, consistent with the paper's conclusion that METTL13 targeting can counteract KRASG12C-inhibitor resistance.

Key findings

  • METTL13 loss inhibited growth of sotorasib-resistant KRASG12C lung adenocarcinoma patient-derived xenografts.
“METTL13 loss inhibited the growth of KRASG12C inhibitor (sotorasib)-resistant lung adenocarcinoma ... patient-derived xenografts.”
What this piece can’t prove
  • Information is limited to the abstract: no quantitative results, sample sizes, or statistical analyses are provided there.
  • The abstract does not specify experimental details for the PDX experiments (e.g., whether METTL13 was genetically ablated or pharmacologically inhibited, number and origin of PDXs, dosing/regimen of sotorasib).

1 further detail could not be confirmed from the summary.

6in vivo animalTargeting/ablating METTL13 mitigates resistance to KRASG12C inhibitors (e.g., sotorasib) and improves tumour control and survival in multiple in vivo cancer models (syngeneic tumours, PDX, and autochthonous relapsed KRASG12C-driven lung adenocarcinoma).Expand

In plain English

In an autochthonous (in situ) relapsed KRASG12C-driven lung adenocarcinoma model, genetic ablation of METTL13 mitigated resistance to the KRASG12C inhibitor sotorasib and significantly extended survival in vivo, as reported in the paper abstract.

Key findings

  • METTL13 ablation mitigated resistance to the KRASG12C inhibitor sotorasib and significantly extended survival in a relapsed autochthonous KRASG12C-driven lung adenocarcinoma model in vivo (abstract).
“In relapsed autochthonous KRASG12C-driven lung adenocarcinoma, METTL13 ablation mitigated sotorasib resistance and significantly extended survival in vivo.”
What this piece can’t prove
  • The abstract does not specify experimental timing (when METTL13 ablation was performed relative to treatment/relapse), criteria used to define relapse, or censoring procedures for survival analysis.

3 further details could not be confirmed from the summary.

7human in vivoIn patients treated with KRASG12C inhibitors, inferred METTL13 activity is associated with inferior clinical response.observational clinical cohort analysisExpand

In plain English

In a cohort of patients treated with KRASG12C inhibitors, computationally inferred METTL13 activity was associated with inferior clinical response. The analysis used a patient cohort receiving KRASG12C inhibitor therapy and a derived METTL13 activity score to model associations with treatment response; the abstract provides no cohort size, inference method details, outcome definitions, or statistical estimates.

Key findings

  • Among patients receiving a KRASG12C inhibitor, inferred METTL13 activity was associated with inferior clinical response.
“Among patients receiving a KRASG12C inhibitor, inferred METTL13 activity was associated with inferior clinical response.”
What this piece can’t prove
  • Association is based on an inferred/derived biomarker score rather than direct measurement, limiting interpretability of the biological mechanism at the patient level.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.